for industry for drug products containing the following active ingredients:

TABLE 2—REVISED DRAFT PRODUCT-SPECIFIC GUIDANCES FOR DRUG PRODUCTS

Active ingredient(s)

Acyclovir.

Baricitinib.

Calcium carbonate; Famotidine; Magnesium hydroxide.

Daunorubicin citrate.

Deferiprone.

Ethinyl estradiol; Norethindrone acetate.

- Ferric oxyhydroxide (multiple reference listed drugs).
- Goserelin acetate (multiple reference listed drugs).
- Icosapent ethyl.
- Lapatinib ditosylate.

Lidocaine.

Oxycodone.

- Progesterone.
- Ranolazine.

Rifaximin.

Sodium phosphate, dibasic, anhvdrous; So-

dium phosphate, monobasic, monohydrate. Sumatriptan succinate (multiple product-specific guidances).

For a complete history of previously published **Federal Register** notices related to product-specific guidances, go to *https://www.regulations.gov* and enter Docket No. FDA-2007-D-0369.

These draft guidances are being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). These draft guidances, when finalized, will represent the current thinking of FDA on, among other things, the product-specific design of BE studies to support ANDAs. They do not establish any rights for any person and are not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.

# **IV. Paperwork Reduction Act of 1995**

FDA tentatively concludes that these draft guidances contain no collection of information. Therefore, clearance by the Office of Management and Budget under the Paperwork Reduction Act of 1995 is not required.

# V. Electronic Access

Persons with access to the internet may obtain the draft guidance at https:// www.fda.gov/drugs/guidancecompliance-regulatory-information/ guidances-drugs, https://www.fda.gov/ regulatory-information/search-fdaguidance-documents, or https:// www.regulations.gov. Dated: November 15, 2022. Lauren K. Roth, Associate Commissioner for Policy. [FR Doc. 2022–25210 Filed 11–17–22; 8:45 am] BILLING CODE 4164–01–P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

# Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel; Member Conflict.

*Date:* December 2, 2022. *Time:* 11:00 a.m. to 1:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6710B Rockledge Drive, Room 2131B, Bethesda, MD 20892–7510 (Virtual Meeting).

*Contact Person:* Jolanta Maria Topczewska, Ph.D., Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute Health, 6710B Rockledge Drive, Room 2131B, Bethesda, MD 20892, (301) 451–0000, jolanta.topczewska@nih.gov.

*Name of Committee:* National Institute of Child Health and Human Development Special Emphasis Panel; Capstone Centers for Multidisciplinary Research in Child Abuse and Neglect.

*Date:* December 8–9, 2022.

*Time:* 9:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6710B Rockledge Drive, Room 2137C, Bethesda, MD 20892–7510 (Virtual Meeting).

*Contact Person:* Kimberly L. Houston, MD, Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institute Health, 6710B Rockledge Drive, Room 2137C, Bethesda, MD 20892, (301) 827–4902, kimberly.houston@nih.gov.

*Name of Committee:* National Institute of Child Health and Human Development Special Emphasis Panel; Program Project Grants for HIV Research.

Date: December 13-14, 2022.

*Time:* 10:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6710B Rockledge Drive, Room 2121B, Bethesda, MD 20892–7510 (Virtual Meeting). *Contact Person:* Christiane M. Robbins,

Contact Person: Christiane M. Robbins, Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute Health, 6710B Rockledge Drive, Room 2121B, Bethesda, MD 20817, (301) 451–4989, crobbins@mail.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. (Catalogue of Federal Domestic Assistance Program Nos. 93.865, Research for Mothers and Children, National Institutes of Health, HHS)

Dated: November 14, 2022.

#### David W. Freeman,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–25165 Filed 11–17–22; 8:45 am] BILLING CODE 4140–01–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## National Institutes of Health

# Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Cardiovascular Sciences.

*Date:* December 7, 2022.

Time: 8:00 a.m. to 12:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Imoh S. Okon, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20817, 301–347–8881, *imoh.okon@nih.gov*.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Acute Neural Injury and Epilepsy.

*Date:* December 7, 2022.

*Time:* 1:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Paula Elyse Schauwecker, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5201, Bethesda, MD 20892, 301–760–8207, schauweckerpe@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: November 14, 2022.

David W. Freeman,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–25164 Filed 11–17–22; 8:45 am] BILLING CODE 4140–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

# Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA–RM– 22–017 Somatic Cell Genome Editing Program Translational Coordination and Dissemination Center.

Date: December 14, 2022. Time: 11:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Rebecca Catherine Burgess, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480–8034, rebecca.burgess@nih.gov.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Topics on Tumor Biology.

*Date:* December 14, 2022.

*Time:* 12:00 p.m. to 6:00 p.m. *Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Jingwu Xie, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–8625, *jingwu.xie@nih.gov*.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member

Conflict: Respiratory Sciences. Date: December 15–16, 2022.

*Time:* 9:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Ghenima Dirami, Ph.D., Scientific Review Officer, Center for

Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4122, MSC 7814, Bethesda, MD 20892, (240) 498– 7546, *diramig@csr.nih.gov*.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Topics in Autoimmunity.

Date: December 15, 2022.

*Time:* 1:00 p.m. to 6:00 p.m. *Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Xinrui Li, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–2084, *xinrui.li@nih.gov.* 

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: November 14, 2022.

#### Tyeshia M. Roberson-Curtis,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–25167 Filed 11–17–22; 8:45 am] BILLING CODE 4140–01–P

## DEPARTMENT OF HOMELAND SECURITY

## **Coast Guard**

[Docket No. USCG-2021-0830]

# National Boating Safety Advisory Committee; Vacancies

**AGENCY:** Coast Guard, Department of Homeland Security. **ACTION:** Request for applications.

**SUMMARY:** The U.S. Coast Guard is accepting applications to fill two vacancies on the National Boating Safety Advisory Committee (Committee). This Committee advises the Secretary of Homeland Security, via the Commandant of the U.S. Coast Guard, on matters relating to national recreational boating safety.

**DATES:** Completed applications must reach the U.S. Coast Guard on or before December 19, 2022.

**ADDRESSES:** Applications must be emailed to Mr. Jeff Decker at *NBSAC@ uscg.mil* with subject line "Application for NBSAC".

FOR FURTHER INFORMATION CONTACT: Mr. Jeff Decker, Alternate Designated Federal Officer of the National Boating Safety Advisory Committee; telephone 202–372–1507 or email at NBSAC@ uscg.mil.

SUPPLEMENTARY INFORMATION: The National Boating Safety Advisory Committee is a Federal advisory committee. The Committee was established on December 4, 2018, by section 601 of the Frank LoBiondo Coast Guard Authorization Act of 2018, Public Law No 115-282, 132 Stat. 4192 (codified, at 46 U.S.C. 15105). The Committee operates under the provisions of the Federal Advisory *Committee Act,* (5 U.S.C. appendix), and 46 U.S.C. 15109. The National Boating Safety Advisory Committee provides advice, consults with, and make recommendations to the Secretary of Homeland Security, via the Commandant of the U.S. Coast Guard, on matters relating to national recreational boating safety.

The Committee is required to meet at least once a year in accordance with 46 U.S.C. 15109(a). We expect the Committee will hold meetings at least twice a year, but it may meet more frequently.

All members serve at their own expense and receive no salary or other compensation from the Federal Government. Members may be reimbursed for travel and per diem in accordance with Federal Travel Regulations.